文献速递脊柱关节炎

美英两国中轴型脊柱关节炎患者阿片类药物处方趋势:近二十年电子健康记录与保险理赔数据分析

Trends in Opioid Prescriptions in Individuals With Axial Spondyloarthritis in the United States and United Kingdom in the Last Two Decades: Analysis of Electronic Health Records and Insurance Claims Data.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2025-10-21

该研究利用英国电子健康记录数据库(2000-2020年)和美国行政理赔数据库(2006-2021年),分析中轴型脊柱关节炎成人患者阿片类药物、非甾体抗炎药及肿瘤坏死因子抑制剂的年度处方率变化。英国阿片处方率总体保持稳定,美国阿片处方率在肿瘤坏死因子抑制剂使用增加背景下略有下降,可能反映2016年美国全国阿片处方指南变化。

要点

  • 英国中轴型脊柱关节炎患者阿片处方率随时间保持稳定(各时段变化95%CI均跨0)。
  • 美国阿片处方率2008-2016年年降1.5%(95%CI -3.0至2.0),2016-2021年年降8.6%(95%CI -15.2至-5.7)。
  • 美国肿瘤坏死因子抑制剂处方率2008-2021年年增1.8%(95%CI 1.1至2.5)。

核心结论

  • 英国阿片处方率随时间保持稳定,而美国在肿瘤坏死因子抑制剂使用增加的同时阿片处方率略有下降。
  • 这些趋势可能反映2016年美国全国阿片处方指南的变化。

研究设计与样本

  • 研究使用英国IQVIA医学研究数据库(IMRD,2000-2020年电子健康记录)和美国Merative MarketScan行政理赔数据库(2006-2021年)。
  • 纳入IMRD中18-89岁及MarketScan中18-65岁的中轴型脊柱关节炎成人患者。
  • 计算阿片类药物、非甾体抗炎药及肿瘤坏死因子抑制剂的年度处方率,并使用连接点回归估计各药物类别的年度处方率百分比变化。

主要发现

  • IMRD纳入1,689例患者(平均年龄47岁;男性74%),MarketScan纳入18,858例患者(平均年龄45岁;男性51%)。
  • IMRD中阿片年度处方率2001-2007年下降2.5%(95%CI -9.1至1.9),2007-2016年上升3.9%(95%CI -3.0至14.2),2016-2020年下降0.4%(95%CI -11.2至2.9)。
  • MarketScan中阿片年度处方率2008-2016年下降1.5%(95%CI -3.0至2.0),2016-2021年下降8.6%(95%CI -15.2至-5.7)。
  • MarketScan中肿瘤坏死因子抑制剂处方率2008-2021年上升1.8%(95%CI 1.1至2.5)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Prolonged opioid use occurs in 25% of individuals with axial spondyloarthritis (axSpA). Whether introduction of tumor necrosis factor inhibitors (TNFi) influenced secular trends in opioid prescription in axSpA is unknown. We examined opioid prescription trends in axSpA, relative to nonsteroidal anti-inflammatory drugs (NSAIDs) and TNFi, using two observational databases. METHODS: We used data from IQVIA Medical Research Database (IMRD), a UK electronic health records-based database from 2000 to 2020, and Merative MarketScan (MarketScan), a US administrative claims-based database from 2006 to 2021. We included adults (18-89 years, IMRD; 18-65 years, MarketScan) with axSpA. We calculated annual prescription rates for opioids, NSAIDs, and TNFi (only in MarketScan) and estimated percentage changes in annual prescription rates by medication class using joinpoint regression. RESULTS: We included 1,689 individuals from IMRD (mean age 47 years; 74% male) and 18,858 individuals from MarketScan (mean age 45 years; 51% male). In IMRD, annual opioid prescription rates decreased by 2.5% (95% confidence interval [CI] -9.1 to 1.9) between 2001 and 2007, increased by 3.9% (95% CI -3.0 to 14.2) between 2007 and 2016, and decreased by 0.4% (95% CI -11.2 to 2.9) between 2016 and 2020. In MarketScan, annual opioid prescription rates decreased by 1.5% (95% CI -3.0 to 2.0) in 2008 to 2016 and decreased by 8.6% (95% CI -15.2 to -5.7) in 2016 to 2021. TNFi prescriptions increased by 1.8% (95% CI 1.1 to 2.5) in 2008 to 2021. CONCLUSION: Opioid prescription rates remained stable over time in the United Kingdom, whereas they slightly decreased in the United States as TNFi uptake increased. These trends may reflect a US nationwide change in guidance for opioid prescriptions issued in 2016.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Degirmenci HB, Peloquin CE, Westerland M, et al. Trends in Opioid Prescriptions in Individuals With Axial Spondyloarthritis in the United States and United Kingdom in the Last Two Decades: Analysis of Electronic Health Records and Insurance Claims Data. Arthritis Care Res (Hoboken). 2025. PMID: 40977482. doi:10.1002/acr.25655

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。